BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Shen NT, Schneider Y, Congly SE, Rosenblatt RE, Namn Y, Fortune BE, Jesudian A, Brown RS. Cost Effectiveness of Early Insertion of Transjugular Intrahepatic Portosystemic Shunts for Recurrent Ascites. Clin Gastroenterol Hepatol. 2018;16:1503-1510.e3. [PMID: 29609068 DOI: 10.1016/j.cgh.2018.03.027] [Cited by in Crossref: 10] [Cited by in F6Publishing: 6] [Article Influence: 2.5] [Reference Citation Analysis]
Number Citing Articles
1 Mattock R, Tripathi D, O'Neill F, Craig J, Tanner J, Patch D, Aithal G. Economic evaluation of covered stents for transjugular intrahepatic portosystemic stent shunt in patients with variceal bleeding and refractory ascites secondary to cirrhosis. BMJ Open Gastroenterol 2021;8:e000641. [PMID: 34429322 DOI: 10.1136/bmjgast-2021-000641] [Reference Citation Analysis]
2 Kwan SW; authors. Reply to: "Details Make the Difference: The Important Need to Accurately Understand the Cost-Effectiveness of Transjugular Intrahepatic Portosystemic Shunts in Patients with Ascites". J Vasc Interv Radiol 2019;30:1311-2. [PMID: 31349980 DOI: 10.1016/j.jvir.2019.04.018] [Reference Citation Analysis]
3 Shen NT, Brown RS Jr, Fortune BE. Details Make the Difference: The Important Need to Accurately Understand the Cost-Effectiveness of Transjugular Intrahepatic Portosystemic Shunts in Patients with Ascites. J Vasc Interv Radiol 2019;30:1310-1. [PMID: 31060771 DOI: 10.1016/j.jvir.2019.01.021] [Reference Citation Analysis]
4 Garbuzenko DV, Arefyev NO. Current approaches to the management of patients with cirrhotic ascites. World J Gastroenterol 2019; 25(28): 3738-3752 [PMID: 31391769 DOI: 10.3748/wjg.v25.i28.3738] [Cited by in CrossRef: 8] [Cited by in F6Publishing: 5] [Article Influence: 2.7] [Reference Citation Analysis]
5 Adebayo D, Neong SF, Wong F. Ascites and Hepatorenal Syndrome. Clin Liver Dis 2019;23:659-82. [PMID: 31563217 DOI: 10.1016/j.cld.2019.06.002] [Cited by in Crossref: 6] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
6 Neong SF, Adebayo D, Wong F. An update on the pathogenesis and clinical management of cirrhosis with refractory ascites. Expert Rev Gastroenterol Hepatol 2019;13:293-305. [PMID: 30791777 DOI: 10.1080/17474124.2018.1555469] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 2.3] [Reference Citation Analysis]
7 Italian Association for the Study of the Liver (AISF). Portal Hypertension and Ascites: Patient-and Population-centered Clinical Practice Guidelines by the Italian Association for the Study of the Liver (AISF). Dig Liver Dis 2021;53:1089-104. [PMID: 34321192 DOI: 10.1016/j.dld.2021.06.021] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
8 Madoff DC, Cornman-Homonoff J, Fortune BE, Gaba RC, Lipnik AJ, Yarmohammadi H, Ray CE Jr. Management of Refractory Ascites Due to Portal Hypertension: Current Status. Radiology 2021;298:493-504. [PMID: 33497318 DOI: 10.1148/radiol.2021201960] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
9 Manning C, Elzubeir A, Alam S. The role of pre-emptive Transjugular Intrahepatic Portosystemic Shunt in acute variceal bleeding: a literature review. Ther Adv Chronic Dis 2021;12:2040622321995771. [PMID: 33747427 DOI: 10.1177/2040622321995771] [Reference Citation Analysis]